BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35782688)

  • 41. [Coexisting mutations in NPM1-mutated elderly adults with acute myeloid leukemia].
    Qin W; Chao HY; Cai XH; Lu XZ; Liu J; Wu P; Chen MY
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3152-3157. PubMed ID: 31694106
    [No Abstract]   [Full Text] [Related]  

  • 42. High
    Dao FT; Chen WM; Long LY; Li LD; Yang L; Wang J; Liu YR; Jiang H; Zhang XH; Jiang Q; Qin YZ
    Leuk Lymphoma; 2021 Jan; 62(1):185-193. PubMed ID: 32902355
    [TBL] [Abstract][Full Text] [Related]  

  • 43. C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics.
    Lu Y; Chen W; Chen W; Stein A; Weiss LM; Huang Q
    Am J Hematol; 2010 Jun; 85(6):426-30. PubMed ID: 20513120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.
    Lyu X; Xin Y; Mi R; Ding J; Wang X; Hu J; Fan R; Wei X; Song Y; Zhao RY
    PLoS One; 2014; 9(3):e92470. PubMed ID: 24667279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic impact of PRDM16 expression in acute myeloid leukemia with normal cytogenetics.
    Xiang X; Lu Q; Xu X; Cai P; Chen S; Pan J; Zeng Z
    Hematology; 2022 Dec; 27(1):499-505. PubMed ID: 35473465
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [FLT3 and NPM1 gene mutations in patients with acute myeloid leukemias and the impact of FLT3-ITD mutations on the survival of patients with a normal karyotype].
    Martynkevich IS; Gritsaev SV; Moskalenko MV; Ivanova MP; Aksenova VIu; Tiranova SA; Abdulkadyrov KM
    Ter Arkh; 2010; 82(12):33-9. PubMed ID: 21516736
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
    Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.
    Schmid C; Labopin M; Socié G; Daguindau E; Volin L; Huynh A; Bourhis JH; Milpied N; Cornelissen J; Chevallier P; Maertens J; Jindra P; Blaise D; Lenhoff S; Ifrah N; Baron F; Ciceri F; Gorin C; Savani B; Giebel S; Polge E; Esteve J; Nagler A; Mohty M;
    Blood; 2015 Oct; 126(17):2062-9. PubMed ID: 26351297
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Frequency of FLT3 Internal Tandem Duplications in Adult Syrian Patients with Acute Myeloid Leukemia and Normal Karyotype.
    Al-Arbeed IF; Wafa A; Moassass F; Al-Halabi B; Al-Achkar W; Abou-Khamis I
    Asian Pac J Cancer Prev; 2021 Oct; 22(10):3245-3251. PubMed ID: 34711001
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
    Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.
    Verhaak RG; Goudswaard CS; van Putten W; Bijl MA; Sanders MA; Hugens W; Uitterlinden AG; Erpelinck CA; Delwel R; Löwenberg B; Valk PJ
    Blood; 2005 Dec; 106(12):3747-54. PubMed ID: 16109776
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.
    Loghavi S; Zuo Z; Ravandi F; Kantarjian HM; Bueso-Ramos C; Zhang L; Singh RR; Patel KP; Medeiros LJ; Stingo F; Routbort M; Cortes J; Luthra R; Khoury JD
    J Hematol Oncol; 2014 Oct; 7():74. PubMed ID: 25281355
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation.
    Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Kumar R; Minden MD; Chang H
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):1995-2000. PubMed ID: 32712325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation.
    Chen F; Sun J; Yin C; Cheng J; Ni J; Jiang L; Wang Q; Yu G; Wei Y; Liu X; Sun J; Carter BZ; Jiang X
    Bone Marrow Transplant; 2020 Apr; 55(4):740-748. PubMed ID: 31645666
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FLT3 and NPM1 gene mutations in childhood acute myeloblastic leukemia.
    Mukda E; Pintaraks K; Sawangpanich R; Wiangnon S; Pakakasama S
    Asian Pac J Cancer Prev; 2011; 12(7):1827-31. PubMed ID: 22126574
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The Mutated Gene Sequenced by NGS and the Correlation of Their Coexistent Mutual Exclusiveness in NPM1 Mutated Acute Myeloid Leukemia].
    Dai L; Wang ZL; Qiu GQ; Wu YC; Zhang XW; Xing SS; Wang B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1733-1740. PubMed ID: 34893102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population.
    Suzuki R; Onizuka M; Kojima M; Shimada M; Okamura K; Fukagawa S; Tsuboi K; Kikuchi A; Kobayashi H; Shintani A; Ogawa Y; Kawada H; Hotta T; Ando K
    Int J Hematol; 2007 Dec; 86(5):422-8. PubMed ID: 18192111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.